drugset
drugset / Trial / NCT00277329

Study of XL999 in Patients With Non-small Cell Lung Cancer

NCT00277329 ↗

Phase 2 Terminated 9 enrolled Symphony Evolution, Inc.
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This clinical study is being conducted at multiple sites to determine the activity, safety, and tolerability of XL999 when given weekly to patients with non-small cell lung cancer (NSCLC). XL999 is a small molecule inhibitor of multiple kinases including VEGFR, PDGFR, FGFR, FLT-3, and Src, which are involved in tumor cell growth, formation of new blood vessels (angiogenesis), and metastasis.

Timeline

Start
2005-12
Primary completion
2007-08
Completion
2008-07

Outcome

Outcome not reported

Stopped: “Study was terminated due to cardiac toxicities in the subejcts”

Drugs

EvaluationDrugModalityDoseRoute
Subject XL999 Small molecule 2.4 mg/kg Intravenous

Indications

non-small cell lung carcinoma